Huberman Lab avatar

Dexa/Huberman Lab

Supported byHuberman Lab
Learn more
Published Jun 17, 2024

Dr. Zachary Knight: The Science of Hunger & Medications to Combat Obesity

Dr. Zachary Knight dives deep into the neural and hormonal mechanisms behind hunger, the impact of ultra-processed foods, and the role of dopamine in eating behavior, while unveiling the latest advancements in obesity medications like GLP-1 drugs.
Episode Highlights
Huberman Lab logo

Topics covered

Popular Clips

Questions from this episode

Episode Highlights

  • Mechanisms

    and discuss the mechanisms of GLP-1 drugs, highlighting their impact on appetite and weight loss. These drugs, which have been around since 2005, are known for their safety and unexpected health benefits beyond weight loss 1. explains that GLP-1 has a very short half-life, making it challenging to use directly, but pharmaceutical advancements have stabilized it for effective use 2.

    The first GLP-1 drug that was approved was just this molecule from this lizard, basically. And it's called xenotide and is approved in 2005.

    ---

    These advancements have led to significant improvements in diabetes treatment and weight management.

       

    Development

    The development of GLP-1 drugs has been a journey of incremental improvements. describes how early versions like liraglutide had a half-life of 13 hours, leading to moderate weight loss 3. Over time, newer drugs like semaglutide have extended this half-life to seven days, resulting in more substantial weight loss 3.

    Semaglutide now has a half-life of seven days. So now we've gone from two minutes, 2 hours, 13 hours, seven days, and you can really jack up the concentration with a seven day half-life.

    ---

    These drugs primarily work by reducing appetite, targeting specific neurons in the brain 4.

       

    Innovations

    Looking ahead, the future of weight loss drugs is promising. mentions that pharmaceutical companies are developing GLP-1 plus drugs, which combine GLP-1 agonists with other compounds to enhance weight loss and reduce side effects 5. One such drug, tirzepatide, targets both GLP-1 and another incretin, leading to even greater weight loss 5.

    The results from this drug are incredible. So basically, there's been one phase two trial published, and people lost 25% of their body weight at the end of the, I think it was 48 week period, and they were still losing weight.

    ---

    Other innovations include long-lasting antibodies that maintain weight loss for extended periods, showing the potential for even more effective treatments 6.

Related Episodes